Mesoblast Ltd (MESO) FinancialsMESOMesoblast Ltd

Evaluating the bottom line, Mesoblast Limited maintains a gross margin of 85.19%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -60.31%, while the net margin is -78.22%. These profitability ratios, combined with a Return on Equity (ROE) of -18.22%, provide a clear picture of how effectively MESO converts its operational activities into shareholder value.

In the context of the broader market, MESO competes directly with industry leaders such as DYN and NRIX. With a market capitalization of $1.86B, it holds a significant position in the sector. When comparing efficiency, MESO's gross margin of 85.19% stands against DYN's N/A and NRIX's 100.00%. Such benchmarking helps identify whether Mesoblast Limited is trading at a premium or discount relative to its financial performance.

Mesoblast reported a remarkable revenue growth of 600% to $120.3 million for FY 2026, but still posted a net loss of $57.5 million, reflecting ongoing financial challenges despite operational improvements.